It is apparent that if (or more accurately when) B
Post# of 72446
(Total Views: 426)
Posted On: 07/13/2020 1:15:44 PM
It is apparent that if (or more accurately when) Brilacidin becomes the "go to" treatment for CV19 worldwide, how is IPIX going to ramp up enough manufacturing if it is going to take months just to get enough IV to run trials?
Even worse than delaying human trials would be to succeed at human trials and then still have many thousands of people dying because B-IV is not available. The RBL had to of made known the possibility B-IV may work on many other types of viruses, its already known anti-inflammation use that could be used in many uses needing urgent care for head, lungs, kidneys, and even possibly bowels to some degree so it is not like the inventory would go to waste if it doesn't play out for CV.
I believe the peer reviewed articles are being over hyped in regards to being necessary for govt grant approval. If the data they are receiving was coming from a corporate lab, then peer review is essential. But when the data is coming from your own labs, labs that you set up for being competent and the backbone of national defense in regards to bacterial/viral threats, then that should be good enough without needing others to tell you that your own labs were competent in running their investigations.
Govt can bring in millions of doses of other extremely iffy drugs yet one that looks strong, according to their own labs, has to scratch for manufacturing sites. Major disconnect from reality there IMO.
I am in favor of IPIX running a small private human trial in Europe or Asia ASAP to get additional data to aid in setting up the USA human trial. Would also let American medicine realize their pace of play isn't cutting it.
Even worse than delaying human trials would be to succeed at human trials and then still have many thousands of people dying because B-IV is not available. The RBL had to of made known the possibility B-IV may work on many other types of viruses, its already known anti-inflammation use that could be used in many uses needing urgent care for head, lungs, kidneys, and even possibly bowels to some degree so it is not like the inventory would go to waste if it doesn't play out for CV.
I believe the peer reviewed articles are being over hyped in regards to being necessary for govt grant approval. If the data they are receiving was coming from a corporate lab, then peer review is essential. But when the data is coming from your own labs, labs that you set up for being competent and the backbone of national defense in regards to bacterial/viral threats, then that should be good enough without needing others to tell you that your own labs were competent in running their investigations.
Govt can bring in millions of doses of other extremely iffy drugs yet one that looks strong, according to their own labs, has to scratch for manufacturing sites. Major disconnect from reality there IMO.
I am in favor of IPIX running a small private human trial in Europe or Asia ASAP to get additional data to aid in setting up the USA human trial. Would also let American medicine realize their pace of play isn't cutting it.
(7)
(0)